Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05835245
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- National Cancer Center, Japan
- Target Recruit Count
- 35
- Registration Number
- NCT05832827
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo, Tokyo, Japan
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 33
- Registration Number
- NCT05824468
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT05822752
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
🇮🇹IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 253247, Bologna, Emilia-Romagna, Italy
🇺🇸Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 32
- Registration Number
- NCT05824481
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05823987
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
- Conditions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Regina Elena Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05789667
- Locations
- 🇮🇹
Regina Elena National Cancer Institute, Rome, Italy
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05781074
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT05775159
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Glenn J. Hanna
- Target Recruit Count
- 10
- Registration Number
- NCT05774899
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.